Eslicarbazepine acetate: Difference between revisions
(Created page with "__NOTOC__ {{Drugbox | IUPAC_name = (''S'')-10-Acetoxy- 10,11-dihydro- 5''H''-dibenz[b,f]azepine- 5-carboxamide | image = Eslicarbazepine acetate structure.svg <!--Clinical da...") |
(No difference)
|
Revision as of 21:53, 13 October 2012
| File:Eslicarbazepine acetate structure.svg | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code | |
| Pharmacokinetic data | |
| Excretion | ~90% renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChEMBL | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C17H16N2O3 |
| Molar mass | 296.320 g/mol |
| 3D model (JSmol) | |
| |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Eslicarbazepine acetate (BIA 2-093) is an antiepileptic drug. It is a prodrug which is activated to eslicarbazepine (S-licarbazepine), an active metabolite of oxcarbazepine.[1]
It is being developed by Bial[2] and will be marketed as Zebinix or Exalief by Eisai Co. in Europe and as Stedesa by Sepracor[3] in America.
The European Medicines Agency (EMA) has recommended granting marketing authorization in 2009 for adjunctive therapy for partial-onset seizures, with or without secondary generalisation, in adults with epilepsy.[1] The U.S. Food and Drug Administration (FDA) announced on 2 June 2009 that the drug has been accepted for filing.[3]
Mechanism of action and indications
Eslicarbazepine acetate is a prodrug for S(+)-licarbazepine, the major active metabolite of oxcarbazepine.[4] Its mechanism of action is therefore identical to that of oxcarbazepine. [5] There may, however, be pharmacokinetic differences. Eslicarbazepine acetate may not produce as high peak levels of (S)-(+)-licarbazepine immediately after dosing as does oxcarbazepine which could theoretically improve tolerability.
Like oxcarbazepine, eslicarbazepine may be used to treat bipolar disorder and trigeminal neuralgia.
Patents
The first European patent to protect this drug is Template:Patent. The priority of this European patent is the Portuguese patent application Template:Patent.
References
- ↑ 1.0 1.1 Dulsat, C., Mealy, N., Castaner, R., Bolos, J. (2009). "Eslicarbazepine acetate". Drugs of the Future. 34 (3): 189. doi:10.1358/dof.2009.034.03.1352675.
- ↑ Community register of medicinal products for human use: Exalief
- ↑ 3.0 3.1 Medical News Today: Sepracor's STEDESA (Eslicarbazepine Acetate) New Drug Application Formally Accepted For Review By The FDA
- ↑ Rogawski, MA (2006). "Diverse Mechanisms of Antiepileptic Drugs in the Development Pipeline". Epilepsy Res. 69 (3): 273–294. doi:10.1016/j.eplepsyres.2006.02.004. PMC 1562526. PMID 16621450. Unknown parameter
|month=ignored (help) - ↑ Rogawski MA, Löscher W (2004). "The neurobiology of antiepileptic drugs". Nature Reviews Neuroscience. 5 (7): 553–64. doi:10.1038/nrn1430. PMID 15208697. Unknown parameter
|month=ignored (help)
Template:Anticonvulsants Template:Mood stabilizers Template:Tricyclics
 | This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it. |
- Pages with script errors
- CS1 maint: Multiple names: authors list
- Pages with citations using unsupported parameters
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Anticonvulsants
- Enantiopure drugs
- Dibenzazepines
- Ureas
- Acetate esters
- Portuguese inventions
- Anticonvulsant stubs